Abstract
Once‐daily dosing of the vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine resulted in significant improvement over placebo in patients with tardive dyskinesia (TD) and an underlying psychotic or mood disorder, a Phase 3 trial has found. Soon after the study's publication online March 21 in the American Journal of Psychiatry, the Food and Drug Administration approved valbenazine as the first available treatment for TD (see From the FDA, page 8).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
